Atlas Trials

Mingzhi Zhang

19 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Mingzhi Zhang

RecordFirmDate
CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors (NCT06647329)Mingzhi Zhang2024-12-01
A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma (NCT06683885)Mingzhi Zhang2024-11-20
"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL (NCT06559553)Mingzhi Zhang2024-09-01
A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma (NCT04831658)Mingzhi Zhang2021-03-29
Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma (NCT04083066)Mingzhi Zhang2019-09-05
PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma (NCT04040491)Mingzhi Zhang2019-09-01
PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma (NCT04038411)Mingzhi Zhang2019-04-01
Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL (NCT03707847)Mingzhi Zhang2018-10-01
A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma (NCT03579082)Mingzhi Zhang2018-06-01
A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma (NCT03558412)Mingzhi Zhang2018-06-01

Track Mingzhi Zhang automatically

Every clearance here is in the API, with alerts when new ones post.